Universal Nanoparticle Counting Platform for Tetraplexed Biomarkers by Integrating Immunorecognition and Nucleic Acid Hybridization in One Assay

The development of a simple and universal strategy for simultaneous quantification of proteins and nucleic acid biomarkers in one assay is valuable, particularly for disease diagnosis and pathogenesis studies. Herein, a universal and amplification-free quantum dot-doped nanoparticle counting platfor...

Full description

Saved in:
Bibliographic Details
Published in:Analytical chemistry (Washington) 2021-12, Vol.93 (50), p.16873-16879
Main Authors: Wu, Xi, Li, Rongsheng, Lai, Tiancheng, Tao, Guangyu, Liu, Feng, Li, Na
Format: Article
Language:English
Subjects:
Alzheimer Disease - diagnosis
Alzheimer Disease - genetics
Alzheimer's disease
Amyloid
Amyloid beta-Peptides
Analytical chemistry
Assaying
Biomarkers
Cerebrospinal fluid
Chemistry
Diagnosis
Humans
Hybridization
MicroRNAs - genetics
Multiplexing
Nanoparticles
Neurodegenerative diseases
Nucleic Acid Hybridization
Nucleic acids
Pathogenesis
Proteins
Quantum dots
Room temperature
Tau protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of a simple and universal strategy for simultaneous quantification of proteins and nucleic acid biomarkers in one assay is valuable, particularly for disease diagnosis and pathogenesis studies. Herein, a universal and amplification-free quantum dot-doped nanoparticle counting platform was developed by integrating immunorecognition and nucleic acid hybridization in one assay. The assay can be performed at room temperature, which is friendly for routine analysis. Multiplexed biomarkers associated with Alzheimer’s disease (AD) including proteins and nucleic acids were detected. For simultaneous detection of tetraplex biomarkers, the assay for amyloid β 1-42 (Aβ42), tau protein, miR-146a, and miR-138 presented limit of detection values of 250 pg/mL, 55.7 pg/mL, 52.5 pM, and 0.62 pM, respectively. By spiking all the above four biomarkers in one artificial cerebrospinal fluid sample, the recoveries were found to be 94.7–117.2%. Using tau protein as the model, four measurements in 88 days presented a coefficient of variance of 7.5%. The proposed platform for the multiplexed assay of proteins and nucleic acids presents the universality, reasonable sensitivity, and repeatability, which may open a new door for early diagnosis and pathogenesis research for AD and other diseases.
ISSN:0003-2700
1520-6882
DOI:10.1021/acs.analchem.1c03858